This is a multifaceted, interdisciplinary program whose objectives are the elucidation of the mechanisms by which three human herpes viruses, i.e., herpes simplex virus 1, herpes simplex virus 2, and Epstein-Barr virus, replicate, maintain themselves in latent infection, and transform cells. The facility also serves as the center for teaching predoctoral and postdoctoral trainees supported by a training grant from the National Cancer Institute and by individual fellowship grants from such sources as National Institutes of Health, the American Cancer Society, Damon Runyon-Walter Winchell Foundation, and the Leukemia Society. The shared facility is the Majorie B. Kovler Viral Oncology Laboratories, which has 35,000 gross sq. ft. and 18,000 net sq. ft. It was designed as a containment facility for use with hazardous virus and was built with the aid of grant from the National Cancer Institute. The facility houses the research programs of Drs. Frenkel, Kieff, Roizman and Spear. These programs currently contain approximately 16 postdoctoral trainees and fellows, 23 predoctoral students, and 20 technical personnel. The facility is fully equipped for research work in molecular virology and oncology. It contains an electron microscope with appropriate accessories, a fully equipped dark room with film developing and printing equipment, high- and low-speed centrifuges, scintillation counters, laminar flow rooms and hood, warm rooms and a cold room, an HP9000 computer with graphics and printing peripherals and terminals throughout the building, glassware washing facilities, a conference room, and miscellaneous other equipment that is shared among the various investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-17
Application #
3811697
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188
An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Showing the most recent 10 out of 668 publications